HONG KONG – Denmark's Novo Nordisk A/S has teamed up with Singapore's Duke-NUS Medical School to provide funding for the next three to five years for stem cell-based research aimed at growing heart muscle and retinal cells to treat heart failure and vision loss.
HONG KONG – South Korean bioinformatics company Syntekabio Inc. pocketed $11.2 million in a series B financing to advance two of it core platforms in bioinformatics and AI-driven drug discovery to speed up drug development process.
HONG KONG – China's Asymchem Laboratories (Tianjin) Co. Ltd. joined hands with a top private equity firm and two government-backed parties to spearhead drug innovation in the northeastern city of Tianjin to bring novel drugs from overseas into the Chinese market.
HONG KONG – Hangzhou, China-based Ascletis Pharma Inc. became the first pre-revenue biotech startup to seek public listing in Hong Kong last week. The company plans to use the proceeds to advance its two hepatitis C drug candidates into commercialization in China.
HONG KONG – Nasdaq-listed Chinese vaccine maker Sinovac Biotech Ltd. is on the brink of collapse, as it is undergoing a series of events due to internal disputes concerning its privatization. The company has put its vaccine productions on hold, which may soon have an impact on its business.
HONG KONG – China's Asymchem Laboratories (Tianjin) Co. Ltd. joined hands with a top private equity firm and two government-backed parties to spearhead drug innovation in the northeastern city of Tianjin to bring novel drugs from overseas into the Chinese market.
HONG KONG – Hangzhou, China-based Ascletis Pharma Inc. became the first pre-revenue biotech startup to seek public listing in Hong Kong this week. The company plans to use the proceeds to advance its two hepatitis C drug candidates into commercialization in China.
HONG KONG – Nasdaq-listed Chinese vaccine maker Sinovac Biotech Ltd. is on the brink of collapse, as it is undergoing a series of events due to internal disputes concerning its privatization. The company has put its vaccine productions on hold, which may soon have an impact on its business.
HONG KONG – While the South Korean government's pricing regime is helping to make drugs more affordable in the country, it is also slowing the value growth of the pharmaceutical market and pressuring the sales of innovative drugs.
